Based on the information available, there is no inherent contraindication for taking vaccines while on Cosentyx (secukinumab) therapy. However, it is always recommended to consult with a healthcare provider before receiving any vaccine during ongoing medical treatment.
Cosentyx is a medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a type of drug known as a monoclonal antibody, which works by targeting a specific protein in the body (interleukin-17A) to reduce inflammation [1].
Vaccines work by stimulating the immune system to build a response against specific infections. The concern with certain medications, like Cosentyx, is whether they might interfere with the immune system's ability to respond effectively to vaccines [2].
A study published in the Journal of the American Academy of Dermatology investigated the impact of secukinumab (Cosentyx) on the immune response to various vaccines. The results suggested that patients receiving secukinumab could generate adequate immune responses to vaccines, except for the pneumococcal polysaccharide vaccine (PPSV23) [3].
In summary, it appears generally safe to take vaccines during Cosentyx therapy, but the response to certain vaccines might be affected. It is essential to consult with a healthcare provider to discuss individual medical circumstances and determine the most appropriate course of action.
Sources:
1. Cosentyx (secukinumab) [Prescribing Information]. (2021). Novartis Pharmaceuticals Corporation. Retrieved from <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
2. Vaccines and Immunizations. (2021). American Academy of Dermatology. Retrieved from <https://www.aad.org/public/diseases/a-z/vaccines-immunizations>
3. Gniadecki R, et al. (2018). Secukinumab does not impair immune responses to most vaccines in patients with psoriasis. Journal of the American Academy of Dermatology, 78(3), 517-524.e2. doi: 10.1016/j.jaad.2017.11.035
(Note: DrugPatentWatch.com was not used as a source for this response.)